title: Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
abstract: BACKGROUND
  Advanced glycation end products (AGEs) are associated with comorbidity and death among patients on hemodialysis (HD). Angiotensin II type 1 receptor blockers (ARBs) can decrease the formation of AGEs in vitro. This study examines the ability of various ARBs to decrease plasma AGE levels in hypertensive patients on HD.
  
  
  METHODS
  This preliminary randomized prospective study included 24 hypertensive patients on HD who were treated with candesartan (8 mg/day). The patients were randomly assigned to an olmesartan (20 mg/day, n = 12) or a telmisartan (40 mg/day, n = 12) group and followed up 24 weeks. Blood pressure was monitored before each HD session, and plasma pentosidine, N-(epsilon)-carboxymethyl-lysine (CML), serum malondialdehyde-low-density lipoprotein (LDL), high-sensitive CRP, and serum total free radical (TFR) were measured at baseline, and at 4, 12, and 24 weeks.
  
  
  RESULTS
  Olmesartan was significantly associated with decreased systolic blood pressure compared with telmisartan. After 24 weeks of treatment, plasma pentosidine and CML levels were significantly decreased and serum TFR levels tended to be decreased in the olmesartan group, but remained unchanged in the telmisartan group.
  
  
  CONCLUSIONS
  These results suggest that olmesartan can help to decrease plasma AGE levels in patients on HD.
authors.affiliation: Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan. hondah@med.showa-u.ac.jp
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Honda
authors.forename: Nozomu
authors.initials: N
authors.lastname: Hosaka
authors.forename: Yumie
authors.initials: Y
authors.lastname: Aoshima
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hirai
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Michihata
authors.forename: Tadao
authors.initials: T
authors.lastname: Akizawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D006977:Hypertension, Renal / Q000097:blood / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D000068557:Olmesartan Medoxomil; D018384:Oxidative Stress / Q000187:drug effects; D010865:Pilot Projects; D011446:Prospective Studies; D006435:Renal Dialysis; D000077333:Telmisartan; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D017127:Glycation End Products, Advanced; D007093:Imidazoles; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil; C048496:N(6)-carboxymethyllysine; D001120:Arginine; C062187:pentosidine; D008239:Lysine; D000077333:Telmisartan